Objective: Restenosis following angioplasty involves processes that may be influenced by local production of cytokines. We investigated the expression of active and total transforming growth factor b (TGFb) following porcine coronary angioplasty (PTCA), and have correlated this with the expression of potential in vivo activators of TGFb: mannose-6-phosphate / insulin-like growth factor-II (M6P/ IGF-II) receptor and thrombospondin-1. Methods: Oversized porcine PTCA was performed and the arteries excised after selected intervals. Levels of in situ active and total (active plus latent) TGFb were determined using a modified plasminogen activator-inhibitor / luciferase bioassay. Results: Levels of active TGFb significantly increased 2 h to 7 days after angioplasty, compared to non-injured controls. Levels returned to baseline by 28 days. Active TGFb in tissues adjacent to the injured artery did not change. Total TGFb was significantly higher than controls 2-6 h after injury. M6P/ IGF-II receptor mRNA was upregulated between 6 h and 3 days after injury, with protein detectable at 3-28 days. Thrombospondin-1 was detected between 1 h and 14 days. Conclusions: We conclude that balloon injury causes an early rapid increase in levels of active TGFb, that correlates with the expression of TGFb activators. Thus, TGFb is a good potential target for anti-restenotic therapies.
Introduction
infiltrating inflammatory cells at the site of injury [6] ; and the expression of big-h3, a TGFb-inducible cell-adhesion Restenosis following percutaneous transluminal coromolecule, is elevated in restenotic lesions [7] . We show nary angioplasty (PTCA) occurs in 30-40% of patients here that TGFb1 protein is present in vascular smooth undergoing this procedure. The biological mechanisms are muscle cells after PTCA in the porcine model, and others complex, involving recoil, extracellular matrix production, have shown that it may modulate the differentiation of cellular proliferation and contraction of the vessel. A adventitial fibroblasts to myofibroblasts [8] . In addition, number of these processes are analogous to wound healing direct gene transfer of a TGFb1 expression plasmid into and scar formation elsewhere in the body. Transforming normal porcine arteries causes neointimal thickening and growth factor-b (TGFb) has potent effects in the process extracellular matrix production [9] . However, no study has of wound healing [1] [2] [3] and also appears to have a role in thus far been able to distinguish whether the TGFb the arterial response to injury. The TGFb gene is expressed detected is in its active or latent state in the artery wall. in human restenotic lesions [4] . Synthesis of TGFb is Scar-free healing is a characteristic of fetal incisional induced by interleukin-1b [5] , which is released from wounds where, compared to adult scar-forming wounds, there is reduced inflammation and TGFb expression [10, 11] . Mimicking the TGFb profile of a fetal wound, by application of TGFb neutralising antibodies to an adult controls. All arteries were serially cross-sectioned, without wound at the time of injury, results in reduced scar further dissection, into 2-3 mm thick blocks (12-14 per formation [12, 13] . This approach has also been successful artery) and sequential blocks were preserved in liquid in inhibiting intimal hyperplasia in a rat carotid injury nitrogen, formalin-fixed and embedded into paraffin wax, model [14] .
or embedded into 8% methylcellulose and frozen slowly in TGFbs are secreted associated with a latency associated liquid nitrogen, prior to subsequent analysis. Samples of peptide (LAP) as part of a biologically inactive complex myocardium and fat immediately surrounding the excised (L-TGFb) which is unable to interact with cell surface artery were also taken for analysis. receptors. Activation of TGFb is complex. Binding of L-TGFb to the mannose-6-phosphate / insulin-like growth 2.2. Histology-quantitative morphology factor-II (M6P/ IGF-II) receptor, that is itself complexed to the urokinase plasminogen activator receptor, invokes a Transverse coronary artery sections were cut from each conformational change of the molecule, allowing paraffin-embedded block and stained with H&E to deproteolytic cleavage of the active TGFb out of the latent termine the location and extent of injury. Arterial blocks complex [15, 16] . Plasmin, under the control of tissue with definite evidence of balloon injury (disruption in the plasminogen activator, urokinase plasminogen activator internal elastic lamina, IEL) were identified and, together [15, 16] , the plasminogen activator inhibitors (PAI), and with sections from undilated arteries (controls), were used transglutaminase [17] also appear to be required.
for analysis. Sections from apparently non-injured areas of Thrombospondin-1 (TSP-1) is also an important activator angioplastied artery were not used for immunohistochemiof TGFb in vivo [18] . TSP-1 interacts with the N-terminal cal or Western blot analysis because of the possibility of region of the LAP, forming a trimolecular complex within unseen damage caused by the angioplasty catheter affectwhich a conformational change takes place, altering the ing the interpretation of data. However, non-injured areas immunoreactivity of TGFb, and making it accessible to its of angioplastied arteries (embedded into methylcellulose) receptor [19] [20] [21] . In activated macrophages, the TSP-1 were analysed for TGFb levels via the PAI / L assay, and receptor, CD36, is also involved [22] , localising the TSPtreated as a separate group of data. 1 / L-TGFb complex to the cell surface and making it accessible to cleavage by plasmin.
2.3. Determination of active and latent TGFb Notwithstanding these data, there is considerable debate regarding the precise role of TGFb in the arterial response
The amount of active and latent TGFb present at each to injury. This arises because of the very considerable timepoint was detected using a modified plasminogen uncertainties regarding the measurements of active and activator-inhibitor / luciferase (PAI / L) assay [24] . Briefly, total TGFb, the (until recently) poorly understood mechamink lung epithelial cells (MLECs) stably transfected with nism of TGFb activation, as well as the non-viability of a truncated TGFb-inducible PAI-1 promoter fused to a TGFb knockout mice. We report here the results of a study firefly luciferase reporter gene (generating a highly sensiof porcine coronary artery injury where a novel bioassay tive TGFb-responsive cell line [25] ), were plated into for TGFb has been used that accurately assesses active 24-well plates in complete DMEM and allowed to attach. TGFb levels following angioplasty, for the first time. This
The serum-containing medium was then replaced with has been correlated with TSP-1 levels and expression of serum-free DMEM containing 0.1% (w / v) pyrogen-poor the M6P/ IGF-II receptor complex.
BSA (DMEM-BSA medium), and sterile coverslips carrying 20 mm cryosections placed, upside down, onto the MLECs. Each coverslip contained a single arterial tissue 2. Methods section, which had been trimmed of extra-arterial myocardial tissue prior to embedding into methylcellulose. A 2.1. Porcine coronary angioplasty model standard curve of TGFb activity was generated using serial dilutions of recombinant human TGFb1 (R&D Systems). Coronary artery injury was induced by oversized PTCA Triplicates of each sample and TGFb standard were of the left anterior descending (LAD) and the right incubated with the MLECs overnight at 378C. The MLECs coronary artery (RCA) in 20 Yorkshire White pigs, [25] [26] [27] [28] [29] [30] were then washed with PBS, lysed, and luciferase activity kg in weight, as previously described [23] . The invesin the lysates determined using a luciferase assay kit tigation conforms with UK Home Office regulations. The (Labtech), measured with a luminometer. site of balloon inflation was selected such that the balTotal (active plus latent) TGFb in the arteries was loon:artery ratio was 1.25:1, as assessed by quantitative determined by submerging the coverslips carrying the angiography. At selected intervals (1, 2, 6, 18 h and 3, 7, cryosections in DMEM-BSA medium and incubating at 14, 28 days) post-PTCA, the animals were sacrificed and 808C in order to heat activate latent TGFb. The coverslips the heart excised. The angioplastied vessels were identified were then transferred, together with the medium, onto and removed, preserving the adventitia. The circumflex MLECs for TGFb quantification in the PAI / L assay. coronary artery was also explanted and used as untreated
The amount of TGFb present in each section was normalised to tissue volume. The volume of the tissue Briefly, sections were dewaxed and rehydrated, endogensections was measured from serial cryosections from the ous peroxidases blocked by incubation with 3% hydrogen same specimen, stained with H&E. Colour images of each peroxide, and non-specific antibody binding blocked by section were captured using a digital image analysis incubation with a 1% (w / v) dried milk / PBS solution prior system and the total coronary artery cross-sectional area of to incubation with the primary antibody. Antigen-unmaskthe section measured. The volume of each section was then ing was required for TSP-1 and mac-387 staining, using calculated from the area and thickness of the section. The
Pronase E digestion and trypsin digestion, respectively. 3 average volume of one artery section was 0.08-0.2 mm .
Primary antibodies were applied for 1 h at 228C (TSP-1, mac-387) or overnight at 48C (TGFb), using 0.5% (w / v) 2.4. Western blotting dried milk / PBS as diluent. Sections were washed with PBS prior to incubation with secondary antibodies, folLevels of TSP-1 were determined by Western blotting.
lowed by peroxidase-anti-peroxidase (PAP) complex (TSPProtein from each timepoint was extracted into RIPA lysis 1) or avidin-biotin complex (ABC) (TGFb, mac-387). buffer (1% Nonidet-P40, 0.5% sodium deoxycholate, 0.1% Finally, antibody binding was visualized with SDS) and 50 mg of each sample separated by SDS-PAGE, 3,39diaminobenzidine tetrahydrochloride (DAB) and counfollowed by semi-dry transfer onto nitrocellulose memterstained with Carazzi's haematoxylin. brane. The membrane was blocked with 5% (w / v) dried M6P/ IGF-II receptor was localised within cryosections milk-TBS prior to incubation with monoclonal anti-TSP-1 cut from the same arterial segments used in the PAI-I / L antibody (NeoMarkers). The membrane was then washed assay and acetone fixed prior to storage, following the with 0.1% Tween-20 / TBS before incubation with HRPprotocol described in [26] . Briefly, sections were thawed labelled secondary antibody. Protein bands were visualised before blocking non-specific binding with 5% (w / v) dried using ECL (Amersham Pharmacia Biotech) and band milk / PBS. Primary antibody (1:1500 in 5% (w / v) dried intensity determined by densitometry using NIH IMAGE, milk / 0.5% (v / v) Triton X-100 / PBS; gift to MWJF) was with each sample normalised to the loading control, aapplied overnight at 48C before detection via a biotinylated tubulin.
secondary antibody and ABC. Antibody binding was visualised with DAB and counterstained with Carrazzi's 2.
RT-PCR
haematoxylin. For all immunohistochemistry experiments, negative RNA was isolated from segments of control and angiopcontrols were performed. Sections were incubated with the lastied arteries from each timepoint, and M6P/ IGF-II omission of primary antibody (substituting antibody dilreceptor mRNA identified using RT-PCR with b-actin as a uent or the appropriate non-immune IgG in each case). control gene transcript. Total RNA was reverse-transcribed Only negative control sections stained with non-immune using standard techniques, and RNA:cDNA hybrids used IgG gave some slight non-specific staining. Antibody immediately as template for RT-PCR. Negative controls, specificity was confirmed using appropriate positive consubstituting water for RNA and cDNA, and the omission trol tissue. of RT or Taq enzymes, were performed to exclude genomic DNA contamination. Thermal cycling consisted 2.7. Statistics of 1 min denaturation at 958C, 1 min annealing at 608C and 1 min extension at 728C. Primer sequences for porcine
Comparisons between control arteries and active or total M6P/ IGF-II receptor were: 59GGA CTA TCT GGA GAG TGFb expression at each timepoint after PTCA were made CAG GAA 39 (forward), 59 CAT TCA TCG CCT CCA using the Kruskal-Wallis test (nonparametric ANOVA) AAA TA 39 (reverse), expected product size 302 bp.
followed by Dunn's multiple comparison test. The TukeyPrimer sequences for b-actin were as previously described Kramer multiple comparisons test was used to compare [6] . PCR products were resolved by agarose gel electrodifferences between active TGFb levels in injured angiopphoresis and visualized by ethidium bromide staining under UV transillumination. The identity of both products Table 1 was confirmed by dideoxy sequencing. porcine models, the macrophage / granulocyte marker Mac-28 days 2 5 387 (Dako) was used to define 'inflammatory cells'. lastied arteries, non-injured angioplastied arteries and nonTGFb in the endothelium and media of control arteries, angioplastied arteries. Values of P,0.05 were considered with the remnants of endothelium in all the injured significant.
sections staining positively at up to 18 h. After injury, the staining pattern of TGFb altered, appearing more diffuse. TGFb was found in neointima from 7 to 28 days; in the 3. Results media throughout, but maximally at 3 days; and in the adventitia between 3 and 14 days, returning to baseline by The 28 coronary arteries which had undergone PTCA 28 days (Fig. 2) . TGFb was also found in the inflammayielded 80 sections (5-19 per timepoint) with evidence of tory cell infiltrate (defined by mac-387 staining, not injury (Table 1) . Twenty-four sections were taken from the shown) at 1-18 h (Fig. 2) . Negative control sections did control arteries (non-angioplastied vessels). Power calculanot stain for TGFb1. tions using a significance level of 0.05 and a power of 90%
Western blotting showed TSP-1 to be expressed between confirmed that the number of arteries and sections analysed 1 h and 14 days post-PTCA (Fig. 3) . Immunohistochemiper timepoint were sufficient for a valid study.
cal staining showed TSP-1 to be absent within non-injured Active TGFb was significantly increased 2 h to 7 days vessels, although residual platelets on the luminal surface post-PTCA compared to control arteries (Fig. 1a) , returnwere positive (Fig. 4a) . As expected, after injury TSP-1 ing to baseline at 28 days. However, there was no was expressed in high levels in the thrombus (Fig. 4b) , significant difference in active TGFb expression over time, located in the platelets and in the fibrous strands. From 1 to except for at day 3 (Fig. 1a) . The level of active TGFb in 6 h after injury TSP-1 expression was detected in some tissue immediately surrounding the injured artery (epimedial cells, although the majority remained negative, cardium / myocardium / fat) were similar to baseline levels however, by 18 h, the media stained strongly for TSP-1 found in non-injured control arteries. Similarly, sections of (not shown). At 6 and 18 h, TSP-1 expression was also angioplastied arteries without evidence of injury displayed detectable in the inflammatory infiltrate present in the a lower level of active TGFb compared to injured sections connective tissues surrounding the artery (Fig. 4b) . The from the same artery (P,0.01) (Fig. 1c) . Total (active plus adventitia stained negatively for TSP-1 until 3 days postlatent) TGFb was also significantly raised between 2 and 6 PTCA, when weak staining was seen in the area of h post-PTCA compared to controls (P,0.001) and over adventitia around the site of breach in the external elastic time (P,0.001 and P,0.01 compared to 3 days, respeclamina (EEL). At 7-14 days, the neointima stained tively), with levels returning to baseline by 3 days. Total strongly for TSP-1 with weaker staining in the neoadvenTGFb then increased again, compared to controls, at 7 titia (Fig. 4c) . At 28 days post-PTCA, levels of TSP-1 days, before returning to baseline by 28 days, although this were almost undetectable by immunohistochemical stainincrease was not statistically significant (Fig. 1b) . From 18 ing, with only the neointima giving a very weak positive h post-PTCA, there was no significant change in total stain. TGFb levels over time.
M6P/ IGF-II receptor RNA was detectable by RT-PCR Immunohistochemistry detected total (active plus latent) in control vessels and in injured arteries between 2 h and 14 days post-PTCA, with increased levels at 2 h to 3 days platelets accumulate at the site of damage following PTCA (Fig. 5) . Immunohistochemical staining showed the M6P/ and release their stores of TGFb this may be the source of IGF-II receptor to be absent in non-injured vessels (Fig. the initial rise in total TGFb levels seen within hours of 6a). The inflammatory infiltrate also stained negatively at injury. In the porcine PTCA model, there is also an influx all timepoints after injury (Fig. 6b) . At 3 days, weak of inflammatory cells, including macrophages, within positive staining was seen in the adventitial cells around hours of injury [27] . The timing of this inflammatory the site of breach in EEL (Fig. 6c and d) . The neointima influx coincides with that of the initial rise in TGFb levels stained strongly for the M6P/ IGF-II receptor at 7-14 days, and thus, may also contribute to active TGFb levels within with sparser staining at 28 days ( Fig. 6e and f) . the arterial wall. Three days after PTCA, polymorphonuclear leukocytes and VSMCs, both sources of TGFb, are present in thrombus-filled breaches in the media. Adventi-4. Discussion tial expansion is also first observed at this timepoint, with a-smooth muscle actin-positive cells present for the first This is the first study to describe the active and latent time in the neoadventitia. Adventitial cells, 3 days poststate of TGFb in the artery after PTCA, and to correlate PTCA, also express high levels of IL-1b [6] , which is the presence of active TGFb with that of its activators. The known to induce expression of TGFb. Alternatively, or study shows that TGFb is present in its active state additionally, the level of TGFb activity seen at 3 days may following PTCA and that the M6P/ IGF-II receptor and be due to the release of active TGFb from pools of soluble TSP-1, both involved in the activation of TGFb in vivo, or extracellular matrix TGFb-binding proteins [28] [29] [30] [31] [32] [33] [34] [35] [36] , or are upregulated with a temporal relationship to TGFb that from the release of the small L-TGFb complex from the suggests latent TGFb may be activated at the site of injury fibrin clot following the degeneration of the clot by by these mechanisms.
plasmin [37] , or by endothelial cells and fibroblasts which Active TGFb levels are significantly increased between migrate into the injured area, and which may produce and 2 h and 7 days after PTCA. This activation pattern is activate TGFbs [14, 38] . similar to that seen during the healing of rodent dermal
It is likely that all of these potential sources of TGFb wounds [24] . Immediately after wounding, platelets accontribute to the presence of TGFb following PTCA cumulate at the site of the wound and are thought be an demonstrated here. This indicates that TGFb production important early source of TGFb after wounding. Since and activation is a central event in the biology of the arterial response to injury. This is reinforced by the cannot be certain of the spatial distribution of the active observation that areas adjacent to the site of injury do not TGFb detected using the PAI / L assay. However, the show any elevation in active or total TGFb as well as the correlation of the temporal pattern of TSP-1 staining with finding of significantly attenuated levels in arteries that that of active TGFb (detected by the PAI / L assay) underwent PTCA but did not demonstrate an injury.
following injury, together with the observation that TGFb Levels of active TGFb in our model correlate with the and TSP-1 are present in the same cell types and layers temporal expression of the L-TGFb activators TSP-1 and within the artery following injury, makes TSP-1 activation M6P/ IGF-II receptor. TSP-1 is secreted by platelets, of L-TGFb feasible. This hypothesis is reinforced by endothelial cells, VSMCs, fibroblasts, macrophages and studies indicating TSP-1 to have both an autocrine and a monocytes and therefore, has the potential to play a paracrine pattern of TGFb activation [18] . significant role in the response to injury. TSP-1 is tran-M6P/ IGF-II receptor expression is detectable by RTscriptionally controlled by a serum-response element that PCR in both control and injured vessels, but is upregulated up-regulates TSP-1 synthesis rapidly after injury and then between 2 h and 3 days after injury. This temporal pattern down-regulates it during later stages of healing or remodelof expression almost exactly correlates with that of active ling when growth factors are low. In our model, Western TGFb, suggesting that this receptor may play a role in the blotting first detected TSP-1 1 h after injury, with levels activation of L-TGFb after PTCA. The spatial expression remaining detectable throughout the timecourse of injury, of the M6P/ IGF-II receptor, detected via immunohistochsuggesting that TSP-1 could be regulating latent-TGFb emical staining, showed the M6P/ IGF-II receptor to be activation after PTCA. Indeed, increased TSP-1 expression present in the neointima at 7-28 days post-injury, directly is frequently associated with increased TGFb activity in correlating with the spatial expression of TGFb in this vivo [39] [40] [41] . We found that TSP-1 after injury was arterial layer. At 3 days, the M6P/ IGF-II receptor was also localised mainly in platelets and thrombus, with a weak detected in adventitial cells located at the site of breach of presence in the media. The inflammatory cell infiltrate also the EEL, in an identical staining pattern to that of TGFb. contained TSP-1 6 h after PTCA. By 18 h, TSP-1 staining However, the M6P/ IGF-II receptor was not detected in the was strong in the media, and remained high until 7 days. media or the inflammatory infiltrate after injury. This At 7 and 14 days post-PTCA, TSP-1 staining was strongest staining pattern suggests that the M6P/ IGF-II receptor is in the neointima. This indicates that the major sources of not involved in L-TGFb activation early (within hours) TSP-1 in the first few hours after PTCA are platelets and after injury but has a potential role to play in TGFb inflammatory cells, and VSMCs from around 18 h. This activation within the neointima, whereas TSP-1 has the agrees with other studies using a rat carotid model of potential to be involved in TGFb activation throughout all injury [42] . Both the media and neointima showed an the arterial layers and at all timepoints. extracellular staining pattern rather than the nuclear stain Our data suggests that at least two mechanisms of TGFb seen with inflammatory cells. This is expected because activation could be employed by the artery following TSP-1 is secreted by VSMCs, fibroblasts, and endothelial balloon injury, the TSP-1 mechanism perhaps being more cells and so would not be totally nuclear in location. The central. Other mechanisms of TGFb activation, involving pattern of TSP-1 localisation also closely correlates with the integrin avb6, have also been reported [43] . However, that of TGFb, which is present in the inflammatory as avb6 is principally expressed on epithelial cells, this infiltrate early after injury, in increased levels in the mechanism is assumed to play an insignificant role in our VSMCs of the media from 6 h and in the adventitia from 3 model. days, and is also highly expressed in the neointima and Our data support strategies that inhibit TGFb activation neoadventitia 7-28 days after injury. In addition, TGFb is to limit neointima formation after PTCA. Neutralising detected in all layers of non-injured arteries. This is to be TSP-1 has been shown to reduce neointima formation in expected as TGFb is ubiquitously expressed, although our balloon-injured rat carotid arteries when delivered intradata from the PAI / L assay suggests it is unlikely to be arterially by use of the dwell technique [44] and it is active. The TGFb antibody used in this study, cannot possible that this reduction in neointima could, in part, be distinguish between active and latent forms. Thus, we due to reduced levels of active TGFb. Inhibiting TGFb 
